22 May 2013
Keywords: aeterna, completes, enrolment, ph, ii, nsclc, trial
Article | 19 November 2007
Canadian drugmaker AEterna Zentaris has completed patient recruitment in its European multicenter Phase II non-small cell lung cancer trial of
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 November 2007
© 2013 thepharmaletter.com